Vertex Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>VP</div>
VRTX -- USA Stock  

USD 212.06  1.68  0.80%

While some baby boomers are getting worried about healthcare space, it is reasonable to break down Vertex Pharmaceuticals Incorpor against economic and market trends. As expected, Vertex Pharmaceuticals is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in Vertex Pharmaceuticals and the market returns of the last few months appear uncorrelated. The appearance of strong technical and fundamental indicators of the company suggests a short-term price swing for investors of Vertex. Vertex Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 5th of May 2021.
Published over three weeks ago
View all stories for Vertex Pharmaceutic | View All Stories
Our current technical analysis of Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX)
Vertex Pharmaceuticals's average rating is Buy from 20 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Vertex Pharmaceuticals market sentiment investors' perception of the future value of Vertex. Let us look at a few aspects of Vertex technical analysis. About 96.0% of the company outstanding shares are owned by institutional investors. Vertex Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.9. The entity recorded earning per share (EPS) of 10.2. The firm had not issued any dividends in recent years. Vertex Pharmaceuticals had 2:1 split on the 24th of August 2000.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Vertex Pharmaceutic. In general, we focus on analyzing Vertex Pharmaceutic stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vertex Pharmaceutic's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Vertex Pharmaceutic's intrinsic value. In addition to deriving basic predictive indicators for Vertex Pharmaceutic, we also check how macroeconomic factors affect Vertex Pharmaceutic price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Vertex Pharmaceutic's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Vertex Pharmaceutic in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Vertex Pharmaceutic. Your research has to be compared to or analyzed against Vertex Pharmaceutic's peers to derive any actionable benefits. When done correctly, Vertex Pharmaceutic's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Vertex Pharmaceutic.

How does Vertex Stands against Peers?

Analyzing Vertex Pharmaceutic competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Vertex Pharmaceutic across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Vertex Pharmaceutic Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Vertex Pharmaceutic, but it might be worth checking our own buy vs. sell analysis

Payment of 311 shares by Bozic Carmen of Vertex Pharmaceutic subject to Rule 16b-3

Legal trades by Vertex Pharmaceutic insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Vertex insider trading alert for payment of common stock by Bozic Carmen, EVP and CMO, on 26th of February 2021. This event was filed by Vertex Pharmaceuticals In with SEC on 2021-02-26. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Vertex Pharmaceuticals Standard Deviation

Vertex Pharmaceuticals Incorpor has current Standard Deviation of 1.67. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.

Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.

Standard Deviation 
=  
SQRT(V) 
 = 
1.67
SQRT = Square root notation
V =   Variance of Vertex Pharmaceuticals returns
Let's now compare Vertex Pharmaceuticals Standard Deviation to its closest peers:
VRTX
MNK
MYL
PFE
VRTX1.67
MNK12.21
MYL2.46
PFE2.0

Vertex technical analysis suggests possible correction

Current Risk Adjusted Performance is up to 0.09. Price may slide again. Vertex Pharmaceuticals Incorpor has relatively low volatility with skewness of -0.47 and kurtosis of 0.88. However, we advise all investors to independently investigate Vertex Pharmaceuticals Incorpor to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Final Take On Vertex Pharmaceuticals

While some other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Vertex Pharmaceuticals may offer a potential longer-term growth to investors. Taking everything into account, as of the 1st of February 2021, our concluding 30 days buy-hold-sell recommendation on the company is Hold. We believe Vertex Pharmaceuticals is fairly valued with very small odds of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Vertex Pharmaceutic. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com